门冬胰岛素30联合阿卡波糖治疗2型糖尿病的临床观察

Clinical observation of type 2 diabetes based on insulin aspart 30 injection combined acarbose tablets treat-ment

目的：探讨门冬胰岛素30联合阿卡波糖（拜糖平）对治疗2型糖尿病患者的临床效果及安全性。方法选择2型糖尿病患者36例，使用门冬胰岛素30联合阿卡波糖治疗，观察治疗前后空腹血糖（FPG）水平、糖化血红蛋白（HbA1c）水平。结果患者空腹血糖值和糖化血红蛋白水平在治疗后[FPG：（6.76±0．47）mmol／L；HbA1c：（7．70±0．82）％]较治疗前[FPG：（10．67±2．00）mmol／L；HbA1c：（9．54±1.90）％]均呈明显下降（t ＝31．920，P ＜0．05；t ＝29．624，P ＜0．05）。结论门冬胰岛素30联合阿卡波糖对于2型糖尿病患者来说，是一种安全、有效且方便的治疗方案。

Objective To discuss the efficacy and safety of insulin aspart 30 injection combined with Akabo Tang （Acarbose tablets）about treatment of patients with type 2 diabetes.Methods 36 cases of type 2 diabetes were selected,by means of insulin aspart 30 combined acarbose tablets treatment,the levels of fasting plasma glucose （FPG）and glycosylated hemoglobin（HbA1c）before and after treatment were observed.Results The levels of fasting plasma glucose were （10.67 ±2.00）mmol/L and （6.76 ±0.47）mmol/L before and after treatment;The levels of HbA1c were （9.54 ±1.90）% and （7.70 ±0.82）% before and after treatment.After treatment,blood glucose and glycated hemoglobin levels in patients were significantly decreased （t =31.920,P 〈0.05;t =29.624,P 〈0.05）. Conclusion The treatment that insulin aspart 30 injection combines acarbose tablets for type 2 diabetes patients is a safe,effective and convenient option.